

October 7, 2026

Company Name	Otsuka Holdings Co., Ltd.
Name of Representative	Makoto Inoue President and Representative Director, CEO
Code Number	4578, Prime market of the Tokyo Stock Exchange
Contact	Yuji Kogure Director, Investor Relations Department (Phone: +81-3-6361-7411)

Otsuka Completes Rolling Submission of Supplemental Biologics License Application (sBLA) for Traditional Approval of VOYXACT® (sibeprenlimab) in U.S.

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that its U.S. subsidiary, Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), completed the rolling submission of a supplemental Biologics License Application (sBLA) to the U.S. FDA on October 6 seeking traditional approval for VOYXACT® (sibeprenlimab), which last year received accelerated approval for the reduction of proteinuria in adults with primary IgA nephropathy (IgAN) at risk for disease progression. There is no change to the Company's consolidated earnings forecast for the fiscal year ending December 2026 at this time. However, the Company regards VOYXACT® as one of its key future growth drivers, and believes that this achievement represents an important milestone toward enhancing its medium- to long-term corporate value.